Reductions in mortality seen in association with ACE inhibitors, beta-blockers, thiazide diuretics<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Sept. 1, 2021 (HealthDay News) — Antihypertensive medication use is associated with a reduction in cancer-specific mortality among patients diagnosed with colorectal cancer (CRC), according to a study published in the August issue of Cancer Medicine<\/em>.<\/p>\n Rajesh Balkrishnan, Ph.D., from the University of Virginia in Charlottesville, and colleagues conducted a noninterventional, retrospective analysis of 13,982 patients aged 65 years and older with CRC diagnosed from Jan. 1, 2007, to Dec. 31, 2012, in the Surveillance, Epidemiology, and End-Results Medicare database. The authors examined the association between antihypertensive drug utilization and the American Joint Committee on Cancer stage I to III CRC mortality rates.<\/p>\n The researchers found that the use of antihypertensive drugs was associated with decreased cancer-specific mortality among patients diagnosed with CRC (hazard ratio, 0.79). Angiotensin-converting enzyme inhibitors, beta-blockers, and thiazide diuretics were associated with decreased mortality (hazard ratios, 0.84, 0.83, and 0.83, respectively). There was also an association between adherence to antihypertensive therapy and reduced cancer-specific mortality (hazard ratio, 0.94).<\/p>\n “The results of this study are novel and suggest future research analyzing the application of antihypertensives as a tool to improve cancer-related mortality,” the authors write.<\/p>\n